Dalton Pharma Services enters into a drug development and manufacturing services agreement with ExCellThera Inc.
TORONTO November 22, 2018
Dalton Pharma Services, a leading North American pharmaceutical cGMP CDMO, is pleased to announce its drug development and manufacturing services agreement with ExCellThera Inc, an innovative biotechnology company focused on delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use.
This agreement provides ExCellThera access to Dalton`s State-of-the-Art cGMP, Health Canada approved biopharmaceutical facility in Toronto, ON, Canada. Under the agreement terms, Dalton will be responsible for the formulation and fill/finish of UM171, a constituent of ExCellThera`s lead technology, ECT-001, to support phase II clinical trials in Canada & the United States.
Stem cell transplantation is a medical procedure that could increasingly be used in the treatment of blood and bone marrow cancers and shows potential for autoimmune disorders and other non-malignant diseases. ECT-001 is a combination of a small molecule, UM171, and an optimized culture system. The technology, capable of expanding the number of stem and immune cells exponentially in as little as seven days, is used in novel curative cord blood transplant therapies for patients with blood cancers, allowing more rapid engraftment, greatly reduced incidence of transplant-related mortality, low risk of chronic graft-versus-host disease and low risk of relapse, resulting in better outcomes for patients.
“Dalton is pleased to apply its expertise in aseptic formulation and sterile fill/finish towards developing this leading-edge therapy. We look forward to working with ExCellThera in support of their efforts to develop ECT-001 as a treatment for blood cancers.” said Peter Pekos, CEO of Dalton Pharma Services.
About ExCellThera Inc.
ExCellThera is a clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for use in novel one-time curative therapies for patients with hematologic malignancies, autoimmune and other diseases.
ExCellThera’s lead solution combines a proprietary small molecule, UM171, and an optimized culture system. In pursuit of better treatments for patients, the company is building out its portfolio of products, as well as supporting best-in-class clinical
trials. For more information, please visit https://excellthera.com.
About Dalton Pharma Services:
Dalton Pharma Services is a leading North American cGMP pharmaceutical organization providing integrated drug discovery, development and manufacturing services. We are FDA registered and Health Canada approved and bring over 30 years of experience to every project. We deliver fully integrated solutions with an emphasis on speed, flexibility and quality. Our integrated services (drug discovery, formulation and process development, custom synthesis, cGMP sterile fill/finish of liquids and powders,
cGMP API manufacturing and/or dosage form manufacturing and Accelerated Stability Testing) all at one location helps us to be adaptable, flexible and cost-effective.
Our CMO 2016, 2017 and 2018 Leadership Awards in the categories of Quality, Reliability, Capabilities, Expertise, Compatibility and Development from Life Science Leader reflect our ongoing commitment to our clients, peers and the business community. Dalton is also named one of the Top 50 Companies to work for in Canada, 2018 and has been re-certified as A Great Place to Work, for a third time in the row.
To learn more about our history and capabilities, please visit http://www.dalton.com.
Peter Pekos
CEO
Dalton Pharma Services
349 Wildcat Road
Toronto, Ontario
Tel: 416-661-2102